SC912

SC912 is an investigational **small-molecule** androgen receptor pathway inhibitor being studied for **castration-resistant prostate cancer**. Preclinical data indicate that it binds the **androgen receptor N-terminal domain**, including both full-length androgen receptor and the splice variant **AR-V7**, with dependence on amino acids 507-531 in the N-terminal domain. By targeting this region, SC912 inhibits AR-V7 transcriptional activity, impairs AR-V7 nuclear localization and DNA binding, suppresses proliferation of AR-V7-positive prostate cancer cells, and induces cell-cycle arrest and apoptosis in preclinical models. The available evidence is from a published preclinical study, and no brand name, commercial manufacturer, or confirmed corporate developer is clearly established from the provided source.